2014-04-01 22:16:29 UTC

Gastroenterology Podcast April 2014: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease

An editorial in the April issue of Gastroenterology compares anti-tumor necrosis factor monotherapy with combination therapy for inflammatory bowel disease. A related article in the same issue also compares increased risk of malignancy with adalimumab combination therapy to monotherapy for Crohn's disease Dr. Kuemmerle speaks with editorial co-author Dr. Corey A. Siegel of Dartmouth-Hitchcock Medical Center; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.

 

 

Bressler B, Siegel CA. Beware of the Swinging Pendulum: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease. Gastroenterology 2014; April; 146(4): 884-887
Full Text

Related:
Osterman MT, Sandborn WJ, Colombel JF, et al. Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease. Gastroenterology 2014; April; 146(4): 941-949
Abstract

 

 

Duration: 18.27m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

More on IBD

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders and get inspired to improve patient care.

Principles of Gastroenterology for the NP and PA

Aug. 11, 2017

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

Link Between Antibiotics and IBD Remains Circumstantial

July 20, 2017

Effect stronger in children, and underscores need for antibiotic stewardship in prescribing for pediatric infections